🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT06788717
Enrolling by invitation Observational

MDR - Comprehensive Primary Revision Stems PMCF

NCT06788717 · tracked via the Priya Life Science Denmark tracker
Phase
Observational
Started
2025-06-19
Last updated
2026-07-09

Condition(s) studied

Shoulder PainShoulder InjuriesShoulder FracturesShoulder DiseaseShoulder Arthritis

Investigational drug(s) / intervention(s)

Comprehensive Primary Revision Stems

Comprehensive Primary Revision Stems: Comprehensive Primary Revision Stem (implants and instrumentation) when used for shoulder arthroplasty.

Study summary

The objective of this retrospective and prospective consecutive series PMCF (Post Market Clinical Follow Up) study is to collect long-term data confirming safety, performance and clinical benefits of the Comprehensive Primary Revision Stems (implants and instrumentation) when used for shoulder arthroplasty at 1, 3, 5, 7 and 10 years.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria * Patient must be 18 years of age or older. * Patient must be willing and able to follow directions. * Study devices must have been implanted following the surgical technique and IFU for the Comprehensive Revision Stem Exclusion Criteria * Off-label use. * Patient is a prisoner. * Patient is a current alcohol or drug abuser. * Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent. * Patient is unwilling to sign informed consent. * Uncooperative patient or patient with neurologic disorders who are incapable of following directions.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Cedars Sinai Medical Center Los Angeles California
Aalborg University Hospital Aalborg Denmark

More Zimmer Biomet trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06788717 on ClinicalTrials.gov ↗ ← All trials in Denmark